Deals
GSK and Hansoh Pharmaceutical’s antibody-drug conjugate success validates their partnership, one of the many deals in which Big Pharma has tapped a China company for promising cancer candidates.
FEATURED STORIES
The total of 52 mergers and acquisitions for the first half of 2026 reflects what analysts, industry watchers and executives are saying over and over: M&A is back.
Dealmaking across biopharma is shifting dramatically as the SEC rolls out new regulations to ease burdens on newly public companies and antitrust review is replaced by drug pricing as the policy concern du jour.
Dual and even triple or quadruple track processes have come roaring back in 2026 thanks to a glut of M&A that has refilled investors’ wallets. Big Pharma is being put on notice that time is critical if they want to acquire.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Gritstone Oncology, Inc. today announced the pricing of its initial public offering of 6,666,667 shares of common stock at a public offering price of $15.00 per share, before underwriting discounts and commissions.
Akari Therapeutics, Plc today announces that it has entered into a Securities Purchase Agreement (the “Agreement”) of up to $20 million with Aspire Capital Fund, LLC
LGC has today announced a further strengthening of its nucleic acid chemistry (NAC) offering with the acquisition of Berry and Associates, premier supplier of specialty oligo reagents.
Clinigen Group plc has agreed to acquire iQone Healthcare Holding, a privately owned Swiss based speciality pharmaceutical business for an initial consideration of €7.5 million (£6.7 million) on a cash free, debt free basis.
Accretive acquisition significantly strengthens Clinigen’s competitive positioning with specialist packaging, labelling, warehousing and distribution capabilities in Europe & the US
Emeryville, Calif.-based Gritstone Oncology hits the ground running today on the Nasdaq Exchange after raising $100 million in an initial public offering.
Fusion Antibodies plc announces that it has been informed by Alan Mawson, a Non-Executive Director of the Company, that on 24 September 2018 he purchased 8,500 ordinary shares in the Company (“Ordinary Shares”) at a price of 67 pence per Ordinary Share via his personal pension scheme.
Swiss-based Roche announced it is buying UK-based Tusk Therapeutics in a deal that could hit $758 million (U.S.).
Karolinska Development’s portfolio company Asarina Pharma will today be listed on Nasdaq First North in Stockholm.
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Syntimmune have just today announced that Alexion will be acquiring Syntimmune, a company working to produce antibody therapeutics that focus on the neonatal Fc receptor (FcRn).